Unbiased Analysis of Today's Healthcare Issues

Last Links Post of 2016

A “shadowy crony group”? The real 2016 celebrity deaths. “The GOP isn’t going to repeal ACA.” Economists versus the Economy. Art of the Deal coming to Rx?

Read the rest of this entry »

Mid-week links

Unified theory of scarcity. Will price transparency cut costs? Potential. Surprise bills. Should academics partner with industry? Giannis!

Read the rest of this entry »

Friday Links

Does risk aversion change after a health shock. DCE vs. BWS. Does insurance cause high pharmaceutical prices? The latest developments in P4P. Drug prices rise, but ROI falls?

Read the rest of this entry »

Friday Links

CON laws don’t reduce mortality Why don’t people like pharma companies? Just give ‘em cash. Is value-based purchasing being undermined? Cancer drugs don’t live up to the hype?

Read the rest of this entry »

Friday Links

The expanding role of MAs. Did the ACA affect breastfeeding rates? Hospital ownership of physician practices. Elephants, poaching and evolution. FDA and Ecstasy. Plus, the one and only Hank Stern hosts the Health Wonk Review: Puppies and Kittens edition.  Check it out!

Read the rest of this entry »

Friday Links

CRISPR=Sputnik 2.0 RIP Leibniz. Budget caps in Germany. Getting value frameworks right. Repeal and delay = the next ‘doc fix’?

Read the rest of this entry »

Friday Links

All or nothing FDA approval. Value of G-CSF. GMOs. “The curious have won.” Clinical trial disclosure. Barriers to value-based agreements. What is NexusACO?

Read the rest of this entry »

Friday Links

Rising drug prices. QPP. Healthcare-wide CER. The age of tech. AI and medicine.

Read the rest of this entry »

Friday Links

Should prisoners get a cure for HCV? Food stamps and beer. Cutting a cake fairly. Uber for caregivers. MSF rejects 1m free vaccines.

Read the rest of this entry »

Friday Links

Health state utilities: Best practices and critique. Health, big data and privacy. Tying drug prices to patient outcomes. Dr. Watson. Absolute vs. relative risk.

Read the rest of this entry »